* Pacific Biosciences of California Inc PACB.OQ
PACB.O is
expected to show a rise in quarterly revenue when it reports
results on August 2.
* The Menlo Park California-based company is expected to
report
a 13.6% increase in revenue to $40.298 million from $35.47
million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Pacific Biosciences
of
California Inc is for a loss of 32 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Pacific
Biosciences of California Inc is $14, above its last closing
price of $13.21.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.33 -0.33 -0.36 Missed -8.3
Dec. 31 2023 -0.37 -0.36 -0.37 Missed -2.4
Sep. 30 2022 -0.33 -0.33 -0.34 Missed -2.5
Jun. 30 2022 -0.32 -0.32 -0.32 Met 1
Mar. -0.31 -0.31 -0.37 Missed -20
31 2022
Dec. 31 2021 -0.28 -0.28 -0.31 Missed -9.4
Sep. 30 2021 -0.22 -0.22 -0.23 Missed -5.7
Jun. 30 2021 -0.20 -0.21 -0.21 Met -1.9
This summary was machine generated August 1 at 02:05 GMT. All
figures in US dollars unless otherwise stated